MRX, Medicis Pharmaceutical Corp.
Medicis Pharmaceutical Corporation (NYSE:MRX) engages in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States, Canada, and Europe.
MRX is dedicated to helping patients attain a healthy and youthful appearance and self-image. MRX's products address various conditions or aesthetic improvements, including facial wrinkles, glabellar lines, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, seborrheic dermatitis, and cosmesis.
MRX's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.
Recently, MRX reported its Fourth Quarter and Year-End 2010 Results
MRX reported revenues of approximately $700.0 million for the twelve months ended December 31, 2010, compared to revenues of approximately $571.9 million for the twelve months ended December 31, 2009, which represents an increase of approximately $128.1 million, or approximately 22.4%.
MRX's Fourth Quarter 2010 Highlights include
Read more at: http://crwepicks.com/?p=13661